Increasing Sales and Expanding Markets: Learn about Milestone’s diagnostic and therapeutic injection technologies

Milestone Scientific
Published on: June 7, 2021
Author: Editor

Milestone Scientific Inc. (NYSE American: MLSS) is a biomedical technology research and development company that patents, designs, and develops innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone recently reported sales for the first quarter of 2021 increased by 61% to $2.9 million, versus $1.8 million for the same period last year. The Company also achieved a strong sequential increase in sales of 32% versus the fourth quarter of 2020. The Company’s proprietary disposables provide recurring revenue with high margins.

The proprietary Dynamic Pressure Sensing (DPS) Technology® platform at the core of the dental and medical portfolio monitors pressure at the tip of a needle for much safer and more precise delivery of anesthesia. The Company has a solid IP portfolio with 20 patents surrounding its injection and drug delivery system. Currently, the Company has two instruments that are FDA approved and have CE Mark certification – CompuFlo Epidural Instrument and the Wand Computer Assisted Anesthesia System.

The CompuFlo Epidural Instrument uses DPS Dynamic Pressure Sensing Technology to achieve 99% percent success in locating the epidural space on the first attempt. The CompuFlo Epidural Instrument has been proven more effective and safer in labor and delivery patients than traditional loss of resistance technique. This can lead to a dramatic improvement in safety, less pain for patients and greater flexibility and cost savings for hospitals.

Specifically, the clinical and safety benefits of the CompuFlo Epidural / CathCheck Systems are backed by extensive published clinical data demonstrating significant reductions in epidural punctures, as well as complication rates, and contributes to a significant savings of time on the part of anesthesiologists. Moreover, the CompuFlo instrument has the potential to significantly reduce costs associated with morbidity, providing a direct economic benefit to healthcare institutions. Similarly, the CathCheck technology has the potential to transform the monitoring of catheter placement following an epidural procedure by confirming the placement of a catheter within 2 minutes, versus 20-40 minutes using conventional methods.

Register now and tune in to the presentation at
10:25 am – 10:45 am PST (1:25 pm – 1:45 pm EST)

GCFF Virtual Conference 2021 – Healthcare Investment Conference

Thursday June 10, 2021
8am – 1pm PST (11am – 4pm EST)

Recent CompuFlo Highlights:

  • Commenced sales of CompuFlo Epidural and CathCheck disposables to three premier medical centers: Regional Medical Center, a premier regional healthcare system in South Carolina; The University of Texas Medical Branch at Galveston (UTMB), an institution of the University of Texas System and agency of the State of Texas; the nationally recognized Medical University of South Carolina; and a leading German hospital, the University Hospital of Würzburg in Germany.
  • Entered into an agreement with Bitmedical AG to distribute the CompuFlo® Epidural Instrument, CathCheck™ System and related disposables in Switzerland and Austria.
  • Awarded a group purchasing agreement for the CompuFlo Epidural System and CathCheck with Premier, a leading healthcare improvement company, uniting an alliance of approximately 4,100 U.S. hospitals and 200,000 other providers to transform healthcare.
  • Publication of a study in the Open Journal of Anesthesiology, in an article entitled, “Confirmation of Epidural Catheter Location by Epidural Pressure Waveform Recordings by the Compuflo® Cath-Checker System,” validating the efficacy of the CompuFlo CathCheck System to confirm the correct placement and positioning of an epidural catheter for use during and after an epidural procedure. CathCheck is expected to significantly reduce both time and cost for medical institutions.

In the dental market, the Wand Computer Assisted Anesthesia System is the market leader in injection technology. The Wand is a computer-assisted system for local anesthesia. The Wand instrument carefully guides dental professionals as they are performing dental injections and ensures virtually painless single tooth anesthesia (STA) with no collateral numbness. 

Milestone has begun implementing its three-year strategy to expand the world-wide global dental market. Milestone expanded its dental distribution network to seven independent distributors in the U.S. and a new distributor in Canada. Through its new decentralized sales strategy, Milestone accomplished its goal of building a robust distribution network in the U.S.   

Biotechnology GCFF